News, musings and commentary on pharmaceutical law issues, technology, and litigation.
No advice, though.
Lawyers for consumers and injured people.(No advice on this blog, though) TOLL FREE 855-525-3955
Tuesday, October 30, 2012
Novo Nordisk Falls as FDA Panel to Discuss Insulin Risks
Novo Nordisk has reported that U.S. regulators disclosed that an advisory panel on the
company’s Tresiba diabetes treatment will focus on heart risks.